Cachexia: A therapeutic approach beyond cytokine antagonism

International Journal of Cardiology

Volumn 85, Issue 1, 2002, Pages 173-183

  Von Haehling, S ^a,b   Genth Zotz, S ^a,c   Anker, S D ^a,b   Volk, H D ^d  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cachexia; Immunosuppression; NF B; Tumor necrosis factor

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN A; CYTOKINE; GLUCOCORTICOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; PROTEASOME INHIBITOR; RAPAMYCIN; TACROLIMUS; THALIDOMIDE; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ACUTE PHASE RESPONSE; CACHEXIA; DRUG TARGETING; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TREATMENT INDICATION;

CACHEXIA; CYTOKINES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; NF-KAPPA B; TRANSCRIPTION FACTOR AP-1; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036051233     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(02)00245-0     Document Type: Review

References (92)

1. Metabolic and nutritional disorders in cardiac cachexia
2. Cardiac cachexia: A syndrome with impaired survival and immune and neuroendocrine activation
3. Cardiac cachexia is a world-wide problem
4. Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway
5. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure
6. The role of cytokines in cancer cachexia
7. Rheumatoid cachexia: Cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation
8. Elevated soluble CD14 receptors and altered cytokines in chronic heart failure
9. Loss of bone mineral in patients with cachexia due to chronic heart failure
10. Weight loss associated with an endotoxin-induced mediator from peritoneal macrophages: The role of cachectin (tumor necrosis factor)
11. Tumour necrosis factor alpha as a predictor of impaired peak leg blood flow in patients with chronic heart failure
12. Tumor necrosis factor in congestive heart failure: A mechanism of disease for the new millennium?
13. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure
14. Plasma cytokine parameters and mortality in patients with chronic heart failure
15. Enhanced generation of interleukins 1 beta and 6 may contribute to the cachexia of chronic disease
16. Leptin, insulin sensitivity and growth hormone binding protein in chronic heart failure with and without cardiac cachexia
17. The acute phase response
18. Cachexia
19. Ubiquitin and proteasome gene expression is increased in skeletal muscle of slim AIDS patients
20. Ubiquitin gene expression in skeletal muscle is increased during sepsis: Involvement of TNF-alpha but not IL-1
21. The expression of genes in the ubiquitin-proteasome proteolytic pathway is increased in skeletal muscle from patients with cancer
22. The acidosis of chronic renal failure activates muscle proteolysis in rats by augmenting transcription of genes encoding proteins of the ATP-dependent ubiquitin-proteasome pathway
23. The N-end rule pathway of protein degradation
24. Evidence that tumor necrosis factor participates in the regulation of muscle proteolysis during sepsis
25. In vivo administration of interleukin-1 alpha induces muscle proteolysis in normal and adrenalectomized rats
26. Interleukin-6 induces skeletal muscle protein breakdown in rats
27. Interaction between corticosterone and tumor necrosis factor stimulated protein breakdown in rat skeletal muscle, similar to sepsis
28. Molecular regulation of muscle cachexia: It may be more than the proteasome
29. Proteasome inhibitors: Valuable new tools for cell biologists
30. Muscle cachexia: Current concepts of intracellular mechanisms and molecular regulation
31. Inhibitors of the proteasome reduce the accelerated proteolysis in atrophying rat skeletal muscles
32. Ubiquitin proteasome pathway: Implications and advances in cancer therapy
33. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin
34. A proteolytic system that compensates for loss of proteasome function
35. Muscle protein waste in tumor-bearing rats is effectively antagonized by a beta 2-adrenergic agonist (clenbuterol). Role of the ATP-ubiquitin-dependent proteolytic pathway
36. Cross-talk between pro-inflammatory transcription factors and glucocorticoids
37. Multiple nuclear factors interact with the immunoglobulin enhancer sequences
38. I kappa B: A specific inhibitor of the NF-kappa B transcription factor
39. NF-κB and Rel proteins: Evolutionarily conserved mediators of immune responses
40. Mutual regulation of the transcriptional activator NF-kappa B and its inhibitor I kappa B-alpha
41. Dimethylfumarate inhibits TNF-induced nuclear entry of NF-kappa B/p65 in human endothelial cells
42. Inflammatory cytokines inhibit myogenic differentiation through activation of nuclear factor-kappaB
43. AP-1: One switch for many signals
44. Cancer cachexia: A therapeutic approach
45. Mechanisms of anti-inflammatory action and of immunosuppression by glucocorticoids: Negative interference of activated glucocorticoid receptor with transcription factors
46. Immunosuppression by glucocorticoids: Inhibition of NF-kappa B activity through induction of I kappa B synthesis
47. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids
48. Mechanism of gene expression by the glucocorticoid receptor: Role of protein-protein interactions
49. Characterization of mechanisms involved in transrepression of NF-kappa B by activated glucocorticoid receptors
50. New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine
51. Biological effects of cyclosporin A: A new antilymphocytic agent
52. Cyclosporin A inhibits IL 2-driven proliferation of human alloactivated T cells
53. Mechanisms of action of cyclosporine
54. Cyclosporine A is an uncompetitive inhibitor of proteasome activity and prevents NF-kappaB activation
55. Cyclosporine a inhibits tissue factor expression in monocytes/macrophages
56. Cyclosporin A inhibits the in vivo production of interleukin-1β and tumour necrosis factor α, but not interleukin-6, by a T-cell-independent mechanism
57. Effect of cyclosporin A on inflammatory cytokine production by U937 monocyte-like cells
58. Effect of cyclosporin A on inflammatory cytokine production by human alveolar macrophages
59. Prevention of adjuvant-induced cachexia in rats by cyclosporin A
60. FK506, an immunosuppressant targeting calcineurin function
61. CsA, FK506, corticosteroids and rapamycin inhibit TNF alpha production by cultured PTEC
62. From beach to bedside: History of the development of sirolimus
63. Inhibition of T and B lymphocyte proliferation by rapamycin
64. Sirolimus interferes with the innate response to bacterial products in human whole blood by attenuation of IL-10 production
65. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones
66. Immunosuppressive and anti-inflammatory properties of interleukin 10
67. Interleukin-10 receptor signalling through the JAK-STAT pathway. Requirement for two distinct receptor-derived signals for anti-inflammatory action
68. Termination of acute-phase response: Role of some cytokines and anti-inflammatory drugs
69. Up-regulation of monocytic IL-10 by tumor necrosis factor-alpha and cAMP elevating drugs
70. Two inhibitors of pro-inflammatory cytokine release, interleukin-10 and interleukin-4, have contrasting effects on release of soluble p75 tumor necrosis factor receptor by cultured monocytes
71. Metabolic-cytokine responses to a second immunological challenge with LPS in mice with T. gondii infection
72. Prevention of adenocarcinoma colon 26-induced cachexia by interleukin 10 gene transfer
73. The treatment of psoriasis with IL-10: Rationale and review of the first clinical trials
74. Interleukin-10 and the interleukin-10 receptor
75. TGF-β signal transduction
76. Proteasomal degradation of Smad1 induced by bone morphogenetic proteins
77. Transforming growth factor-beta 1 inhibits synthesis of cytokines in endotoxin-stimulated human whole blood
78. Chronic administration of transforming growth factor-beta suppresses erythropoietin-dependent erythropoiesis and induces tumour necrosis factor in vivo
79. Transforming growth factor beta 1 induces cachexia and systemic fibrosis without an antitumor effect in nude mice
80. Cloning of the human IL-13R alpha1 chain and reconstitution with the IL4R alpha of a functional IL-4/IL-13 receptor complex
81. IL-4 protects against TNF-alpha-mediated cachexia and death during acute schistosomiasis
82. N-Phthalyl-glutaminsäure-imid
83. Clinical pharmacology of thalidomide
84. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes
85. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum
86. Thalidomide exerts its inhibitory action on tumor necrosis factor α by enhancing mRNA degradation
87. New therapies for heart failure: Is thalidomide the answer?
88. Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis
89. Purification and characterization of a lipid-mobilizing factor associated with cachexia-inducing tumors in mice and humans
90. Characterization of a cancer cachectic factor
91. Characteristics of patients with pancreatic cancer expressing a novel cancer cachectic factor
92. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia